Literature DB >> 8462151

Suppression of protein degradation in progressive cardiac hypertrophy of chronic aortic regurgitation.

N M Magid1, J S Borer, M S Young, D C Wallerson, C DeMonteiro.   

Abstract

BACKGROUND: The heart adapts to the volume overload of aortic regurgitation with dilation and hypertrophy. The development of left ventricular hypertrophy at the protein level is a dynamic process resulting from an imbalance between cardiac protein synthesis and degradation. The objective of the present study was to determine in vivo the relative contributions of cardiac protein synthesis and degradation to the progressive hypertrophy that occurs in response to chronic aortic regurgitation and to compare these with responses earlier in the course of this stress. METHODS AND
RESULTS: Continuous intravenous infusions of [3H]-leucine were administered 3 days and 1 month after surgical induction of aortic regurgitation and sham operation in rabbits. Total cardiac protein and myosin heavy chain fractional synthesis rates were obtained by analysis of plasma and protein hydrolysate data using [14C]-dansyl chloride assays. Left ventricular growth rates were determined from serial echocardiographic and postmortem left ventricular weight and protein concentration measurements; protein degradation rates were determined by subtraction of growth rates from synthesis rates.
CONCLUSIONS: In comparison with sham-operated control rabbits, protein fractional synthesis rates were increased at 3 days but not at 1 month after induction of aortic regurgitation Progressive cardiac hypertrophy occurring at 1 month was caused by a decrease in protein fractional degradation rates. An increase in protein synthesis contributes only to the early phase of hypertrophy caused by acute aortic regurgitation, whereas progressive eccentric hypertrophy in chronic volume overload is due to suppression of protein degradation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8462151     DOI: 10.1161/01.cir.87.4.1249

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

Review 1.  Tear me down: role of calpain in the development of cardiac ventricular hypertrophy.

Authors:  Cam Patterson; Andrea L Portbury; Jonathan C Schisler; Monte S Willis
Journal:  Circ Res       Date:  2011-08-05       Impact factor: 17.367

Review 2.  Management decisions in valvular heart disease: the role of radionuclide-based assessment of ventricular function and performance.

Authors:  J S Borer; D Wencker; C Hochreiter
Journal:  J Nucl Cardiol       Date:  1996 Jan-Feb       Impact factor: 5.952

3.  In vivo measurements of the contributions of protein synthesis and protein degradation in regulating cardiac pressure overload hypertrophy in the mouse.

Authors:  Paul J McDermott; Catalin F Baicu; Shaun R Wahl; An O Van Laer; Michael R Zile
Journal:  Mol Cell Biochem       Date:  2012-05-19       Impact factor: 3.396

4.  Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance.

Authors:  J S Borer; C Hochreiter; E M Herrold; P Supino; M Aschermann; D Wencker; R B Devereux; M J Roman; M Szulc; P Kligfield; O W Isom
Journal:  Circulation       Date:  1998-02-17       Impact factor: 29.690

5.  Sarcoplasmic reticulum Ca2+ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy.

Authors:  M Flesch; R H Schwinger; P Schnabel; F Schiffer; I van Gelder; U Bavendiek; M Südkamp; F Kuhn-Regnier; M Böhm
Journal:  J Mol Med (Berl)       Date:  1996-06       Impact factor: 4.599

6.  Left ventricular and myocyte structure and function following chronic ventricular tachycardia in rabbits.

Authors:  F G Spinale; D M Eble; R Mukherjee; W S Johnson; J D Walker
Journal:  Basic Res Cardiol       Date:  1994 Sep-Oct       Impact factor: 17.165

7.  Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?

Authors:  Xiang Wang; Ana-Maria Bosonea; Jeffrey Odenbach; Carlos Fernandez-Patron
Journal:  Curr Hypertens Rev       Date:  2012-08-01

8.  Time course of changes in the expression of DHPR, RyR(2), and SERCA2 after myocardial infarction in the rat left ventricle.

Authors:  Pirkko Sallinen; Satu Mänttäri; Hanna Leskinen; Mika Ilves; Heikki Ruskoaho; Seppo Saarela
Journal:  Mol Cell Biochem       Date:  2007-05-22       Impact factor: 3.842

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.